Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 614-626-2 | CAS number: 685853-81-0
Endpoint summary
Administrative data
Description of key information
From extensive work on chromium III salts, there is no evidence of acute toxicity. Some corrosive salts will cause harm at high concentrations, but this is not considered to be a toxic effect.
Critic acid is not classified; although some reports on anhydrous citric acid suggest Harmful (considered due to local irritation / corrosion of the anhydrous acid)
In view of the wealth of data on chromium salts and citric acid, no further animal testing is justified.
It is accepted that there is no dermal absorption of metal salts such as chromium III from dermal contact.
The low oral toxicity also suggests low biological impact from contact with chromium III. It is not considered to be justified to perform further animal tests.
Skin penetration experiments on chromium chloride and chromium sulfate (1.2% chromium labelled with 51Cr) with skin chambers glued to the skin of normal volunteers. These chambers were removed at 6, 12, or 24 hours and analysis for radioactive chromium was performed at the site of the chamber as well as in the underlying epidermis and dermis. As no label was found in the lower levels of skin, it was concluded that chromium(III) salts did not permeate through the intact epidermis. Some blood samples and 24-h urine were also examined, and no radioactive chromium was detected.[Mali JWH, Van Kooten WJ, Van Neer CJ (1963) Some aspects of the behaviour of chromium compounds in the skin. Journal of Investigative Dermatology, 41:111–122].
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- All data confirms low oral toxicity of chromium III.
Acute toxicity: via inhalation route
Endpoint conclusion
- Quality of whole database:
- In view of the physical form of the substance, inhalation is not seen as a significant route of exposure. Animal testing is not justifed.
Additional information
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
